



Bharat Immunologicals & Biologicals Corporation Limited

BIBCOL

Regd. Office: Vill.

No.BIB/CS/SE/24A/21-22/2022-23

Date 13.07.2022

To
The Listing Department
Bombay Stock Exchange
Phiroze jeejeebhoy Tower
25, Dalal Street, Mumbai – 400001

Sir/Madam,

In pursuance of the LODR with Stock Exchange, please find attached the Secretarial Audit Report and Compliance certificate for the year 2021-22 from Practicing Company Secretary.

Submitted please.

Thanking you,

Sandip Kumar Lal
(General Manager/Company Secretary)

AGRAWAL MANISH KUMAR & CO.
Company Secretaries

206 & 207, 2nd Floor, Chanakya Complex, B-10
Subhash Chowk Street, Laxmi Nagar, Delhi-92

Phone - 91-11-40546341

Mobile - 9811396826

E-mail - mkagrawal.cs@gmail.com

Form No. MR-3

SECRETARIAL AUDIT REPORT

FOR THE FINANCIAL YEAR ENDED 31st March, 2022

[Pursuant to section 204(1) of the Companies Act, 2013 and rule No.9 of the Companies (Appointment and Remuneration Personnel) Rules, 2014]

To,
The Members,

BHARAT IMMUNOLOGICAL AND BIOLOGICAL CORPORATION LIMITED

I/We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by Bharat Immunological and Biological Corporation Limited (hereinafter called the company). Secretarial Audit was conducted in a manner that provided me/us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing my opinion thereon.

Based on my/our verification of the Bharat Immunological and Biological Corporation Limited books, papers, minute books, forms and returns filed and other records maintained by the company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, I/We hereby report that in my/our opinion, the company has, during the audit period covering the financial year ended on 31st March, 2022 complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

I/we have examined the books, papers, minute books, forms and returns filed and other records maintained by BHARAT IMMUNOLOGICAL AND BIOLOGICAL CORPORATION LIMITED for the financial year ended on 31st March, 2022 according to the provisions of:

- (i) The Companies Act, 2013 (the Act) and the rules made thereunder;
- (ii) The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made thereunder;
- (iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;
- (iv) Foreign Exchange Management Act, 1999 and the rules and regulations made thereunder;
- (v) The Applicable Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'), Viz.:-

- (a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
- (b) Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
- (c) Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2015.

2015.

I/we have also examined compliance with the applicable clauses of the following:

- (i) Secretarial Standards issued by The Institute of Company Secretaries of India.
- (ii) The Listing Agreements entered into by the Company with Bombay Stock Exchange,

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above subject to the following observations: Nil

I/we further report that:

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act. Adequate notice is given to all directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting. Majority



decision is carried through while the dissenting members' views are captured and recorded as part of the minutes.

I/we further report that there are adequate systems and processes in the company commensurate with the size and operations of the company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

Note: On the basis of information provided, I/we do not find any reason to specific observations / qualification, reservation or adverse remarks in respect of the Board Structures/system and processes relating to the Audit period.

Place: New Delhi

Date: 13/07/2022

UDIN : F009528D000616640

for AGRAWAL MANISH KUMAR & CO
COMPANY SECRETARIES



MANISH KUMAR AGRAWAL
(Proprietor)

C.P. NO. 7057

Fellow Membership Number- 9528



AGRAWAL MANISH KUMAR & CO.

Company Secretaries

206 & 207, 2nd Floor, Chanakya Complex, B-10
Subhash Chowk Street, Laxmi Nagar, Delhi-92

Phone - 91-11-40546341

Mobile - 9811396826

E-mail - mkagrawal.cs@gmail.com

SECRETARIAL COMPLIANCE REPORT OF BHARAT IMMUNOLOGICALS AND BIOLOGICALS CORPORATION LIMITED FOR THE YEAR ENDED AS ON 31ST MARCH, 2022

I Manish Kumar Agrawal have examined:

- (a) All the documents and records made available to us and explanation provided by BHARAT IMMUNOLOGICALS AND BIOLOGICALS CORPORATION LIMITED ("the listed entity"),
- (b) the filings/ submissions made by the listed entity to the stock exchanges,
- (c) website of the listed entity,
- (d) any other document/ filing, as may be relevant, which has been relied upon to make this certification,



And based on the above examination, I hereby report that, during the Review Period:

(a) The listed entity has complied with the provisions of the above Regulations and circulars/ guidelines issued thereunder, except in respect of matters specified below:-

Sr. No	Compliance Requirement (Regulations/ circulars/ guidelines including specific clause)	Deviations	Observations/ Remarks of the Practicing Company Secretary
	NIL		

b) The listed entity has maintained proper records under the provisions of the above Regulations and circulars/ guidelines issued thereunder insofar as it appears from my/our examination of those records.

(c) The following are the details of actions taken against the listed entity/ its promoters/ directors/ material subsidiaries either by SEBI or by Stock Exchanges (including under the Standard Operating Procedures issued by SEBI through various circulars) under the aforesaid Acts/ Regulations and circulars/ guidelines issued thereunder:

Sr. No	Action taken by	Details of violation	Details of action taken E.g. fines, warning letter, debarment, etc.	Observation remarks of the Practicing Company Secretary if any.
	Not applicable during the review period			

(d) The listed entity has taken the following actions to comply with the observations made in previous reports:

Sr. No	Observations of the Practicing Company Secretary in the previous reports	Observations made in the secretarial compliance report for the year endeth (The years are to be mentioned)	Actions taken by the listed entity, if any	Comments of the Practicing Company Secretary on the actions taken by the listed entity
	Not applicable during the review period			

Place: New Delhi
Date: 13.07.2022



for AGRAWAL MANISH KUMAR & CO
COMPANY SECRETARIES

(Signature)
MANISH KUMAR AGRAWAL

(Proprietor)

Fellow Membership Number- 9528, Certificate of Practice Number- 7057
UDIN number- F009528D000616299